- Timeline: From 15% Cap Proposal to Final Ruling
- Why the Appeals Court Ruled the Cap Unlawful
- Answer-First Q&A
- What the Ruling Means for Institutions
- What Comes Next for Indirect Cost Policy
The NIH indirect cost cap lawsuit is over. In early April 2026, the deadline for the Trump administration to petition the US Supreme Court over its blocked attempt to cap National Institutes of Health facilities-and-administrative (F&A) reimbursements at 15% passed without a filing, closing out fourteen months of litigation that began with a February 2025 policy notice and ended with a unanimous First Circuit Court of Appeals ruling in January 2026. For research administrators who have spent a year budgeting around uncertainty, the case is now legally settled — though, as this article explains, the underlying policy debate is not.
Timeline: From 15% Cap Proposal to Final Ruling
The dispute began on 7 February 2025, when NIH issued guidance capping reimbursement of indirect costs — overheads such as facility maintenance, laboratory utilities, and administrative support — at 15% for all new and existing grants, replacing rates individually negotiated with each institution that typically ranged from 30% to 70%. Twenty-two state attorneys general, along with universities and organisations including the Association of American Medical Colleges (AAMC), challenged the notice within days.
| Date | Development |
|---|---|
| 7 February 2025 | NIH issues Supplemental Guidance capping indirect cost reimbursement at 15% |
| 10 February 2025 | State attorneys general and higher-education associations file suit |
| 7 April 2025 | US District Court issues a permanent injunction blocking the cap nationwide |
| 6 January 2026 | First Circuit Court of Appeals unanimously upholds the injunction |
| Early April 2026 | 90-day Supreme Court appeal deadline lapses; administration formally drops the case |
NIH’s own public estimate, cited in the appeals court’s opinion, put the fiscal effect of the 15% rate at roughly $4 billion in annual reimbursement withheld from institutions; the AAMC separately estimated the cap would have disrupted $6.5 billion in previously committed research funding had it taken effect immediately.
Why the Appeals Court Ruled the Cap Unlawful
The First Circuit’s 6 January 2026 decision rested on two grounds. First, the panel found that a flat cap conflicts with Department of Health and Human Services regulations requiring indirect cost rates to be individually negotiated with each institution rather than imposed uniformly. Second, and more decisively, the court pointed to an appropriations rider that Congress has re-enacted every year since 2017 explicitly preventing NIH from altering how it reimburses indirect costs outside the negotiated-rate process.
Jurisdiction was itself contested. The administration argued that funding disputes belonged before the Court of Federal Claims rather than a district court, drawing on a Supreme Court precedent from a separate case over NIH grant terminations. Writing for the panel, Judge Kermit V. Lipez distinguished that precedent using Justice Amy Coney Barrett’s concurrence in the earlier grant-termination case, which separated challenges to agency-wide policy (properly heard in district court) from disputes over the withholding of already-awarded contract funds. The proposed rate cap, the court reasoned, was exactly this kind of general policy — so the original district court injunction stood.
With the ruling upheld and no Supreme Court petition filed inside the 90-day statutory window, the injunction is now final and nationwide. The administration also quietly withdrew parallel appeals over comparable rate-cap policies at the Department of Energy, the National Science Foundation, and the Department of Defense, effectively closing the entire family of indirect-cost-cap litigation at once.
Answer-First Q&A
What did the NIH’s proposed 15% indirect cost cap actually change?
The NIH’s February 2025 policy would have replaced individually negotiated facilities-and-administrative rates, which typically ran between 30% and 70%, with a flat 15% cap on all new and existing grants. Institutions, state attorneys general, and higher-education associations argued this ignored real infrastructure costs and breached appropriations law protecting negotiated rates.
Why did the appeals court say the cap was unlawful?
The First Circuit Court of Appeals found the cap violated a Department of Health and Human Services regulation requiring individually negotiated indirect cost rates, plus an appropriations rider Congress has re-enacted since 2017 that bars NIH from unilaterally changing how indirect costs are reimbursed without new legislative authority.
Is the NIH indirect cost cap litigation completely over?
Yes. The Trump administration’s 90-day window to petition the Supreme Court after the January 2026 First Circuit ruling expired in early April 2026 without a filing. That deadline lapse permanently ends the case, leaving the nationwide permanent injunction against the 15% cap in place.
Does the ruling mean indirect cost policy will never change again?
No. The courts blocked only this specific capping mechanism, not future reform. A 2025 executive order still directs federal agencies to favour lower-overhead institutions in funding decisions, and groups such as AAMC continue advancing the FAIR model as a negotiated alternative to a flat cap.
What the Ruling Means for Institutions
For research administrators, the practical effect is restoration of the status quo ante: negotiated F&A rates on NIH awards remain enforceable exactly as they were before February 2025. There is no retroactive cap to reconcile, and no need to budget contingency reserves against a 15% ceiling that never took legal effect. That said, the ruling changes the litigation posture, not the political one — a distinction that matters for planning:
- Negotiated rate agreements stand. Institutions’ existing Facilities and Administrative (F&A) rate agreements with their cognizant federal agency remain the operative basis for NIH indirect cost reimbursement.
- Subaward flow-through is unaffected. The cap would have applied to NIH indirect costs on subawards as well as prime awards; with the injunction final, subrecipient reimbursement continues on negotiated terms.
- Executive-order pressure persists. A separate August 2025 executive order instructing agencies to weight funding decisions toward lower-overhead institutions was not addressed by this litigation and remains in force as a policy lever.
- Watch agency-specific rulemaking. Because the appeals court’s reasoning turned on the specific appropriations rider protecting NIH, institutions should not assume identical legal protection automatically extends to every other federal funder without agency-specific statutory analysis.
- Transparency debate continues. AAMC’s Heather Pierce has been explicit that the litigation’s end does not resolve underlying questions about how explainable indirect cost rates are to Congress and taxpayers — a conversation research offices should expect to continue independent of any court order.
What Comes Next for Indirect Cost Policy
The NIH indirect cost cap lawsuit’s conclusion removes a year of acute legal uncertainty from institutional budgeting, but it does not close the broader policy conversation about how NIH direct and indirect costs are structured, negotiated, or explained. Two threads are worth tracking. First, the AAMC-backed Financial Accountability in Research (FAIR) model proposes a more granular, activity-based way of tracking indirect cost expenses — an alternative to both the old negotiated-rate system and the abandoned flat cap, and one that could shape future NIH grant funding policy change through negotiation rather than unilateral notice. Second, the administration’s remaining lever — the executive order favouring lower-overhead applicants in funding decisions — operates through discretionary award selection rather than rate-setting, so it sits outside what this ruling addressed and could still influence which institutions receive awards even as reimbursement rates themselves stay protected.
For institutions tracking research administration standards and terminology more broadly, CASRAI’s research administration resources and open glossary of research-administration terms provide grounding definitions that sit alongside funder policy developments like this one.
